AU7039391A

AU7039391A – A recombinant human factor viii derivative
– Google Patents

AU7039391A – A recombinant human factor viii derivative
– Google Patents
A recombinant human factor viii derivative

Info

Publication number
AU7039391A

AU7039391A
AU70393/91A
AU7039391A
AU7039391A
AU 7039391 A
AU7039391 A
AU 7039391A
AU 70393/91 A
AU70393/91 A
AU 70393/91A
AU 7039391 A
AU7039391 A
AU 7039391A
AU 7039391 A
AU7039391 A
AU 7039391A
Authority
AU
Australia
Prior art keywords
factor viii
human factor
kda
domain
amino acid
Prior art date
1989-12-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU70393/91A
Other versions

AU645539B2
(en

Inventor
Annelie B Almstedt
Eva Maria Hellstrom
Kerstin Larsson
Peter Lind
Helena Inga Sandberg
Jack Spira
Mona Sydow-Backman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Swedish Orphan Biovitrum AB

Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1989-12-15
Filing date
1990-12-06
Publication date
1991-07-18
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU7039391(A)
«Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-12-06
Application filed by Biovitrum AB
filed
Critical
Biovitrum AB

1991-07-18
Publication of AU7039391A
publication
Critical
patent/AU7039391A/en

1994-01-20
Application granted
granted
Critical

1994-01-20
Publication of AU645539B2
publication
Critical
patent/AU645539B2/en

1996-02-08
Assigned to PHARMACIA AB
reassignment
PHARMACIA AB
Alteration of Name(s) in Register under S187
Assignors: KABI PHARMACIA AKTIEBOLAG

1997-11-13
Assigned to PHARMACIA & UPJOHN AB
reassignment
PHARMACIA & UPJOHN AB
Request to Amend Deed and Register
Assignors: PHARMACIA AB

2002-03-21
Assigned to BIOVITRUM AB
reassignment
BIOVITRUM AB
Alteration of Name(s) in Register under S187
Assignors: PHARMACIA & UPJOHN AB

2015-12-06
Adjusted expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/745—Blood coagulation or fibrinolysis factors

C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P7/00—Drugs for disorders of the blood or the extracellular fluid

A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

Abstract

A DNA sequence coding for a biologically active recombinant human factor VIII derivative, comprising a first DNA segment coding for the 90 kDa chain of human factor VIII and a second DNA segment coding for the 80 kDa chain of human factor VIII, said segments being interconnected by a linker DNA segment coding for a linker peptide of 4 to about 100 amino acid residues of the B domain of human factor VIII, at least 4 of said amino acid residues originating from the C terminal of said domain; recombinant expression vector comprising such DNA sequence; host cells of animal origin transformed with such recombinant expression vector; a process for the manufacture of recombinant human factor VIII derivative; and human factor VIII derivative containing the heavy chain and the light chain linked by metal ion bond.

Description

A recombinant human factor VIII derivative
The present invention relates to a DNA sequence coding for a biologically active recombinant human factor VIII derivative, a recombinant expression vector containing such DNA sequence, host cells transformed with such recombinant expression vector and a process for the manufacture of the recombinant human factor VIII derivative. The invention also covers the human factor VIII derivative comprising two polypeptides linked by a metal ion bridge.
BACKGROUND OF THE INVENTION
Classic hemophilia or hemophilia A is the most common of the inherited bleeding disorders. It is a result of a chromosome X-linked deficiency in blood coagulation factor VIII. It affects almost exclusively males and the incidence is one to two individuals per 10 000 men. The X-chromosome defect is transmitted by female carriers who are not themselves hemophiliacs. Depending on the type of mutation in the X-chromosome, factor VIII is either dysfunctional or absent which leads to a retarded blood coagulation. The clinical manifestation of hemophilia A is an abnormal bleeding tendency and before treatment with factor VIII concentrates was introduced the mean life time for a person with severe hemophilia A was less than 20 years. The use of concentrates of factor VIII from plasma has considerably improved the situation for the hemophilia patients. The mean life time has increased extensively and most of them have the possibility to live a more or less normal life. However, there have been certain problems with the concentrates and their use. The most serious have been the transmission of viruses. Hitherto, viruses causing AIDS, hepatitis B, and non A non B hepatitis have hit the hemophiliac population seriously. Recently, different virus inactivation methods have been introduced in the production process for many commercial concentrates. There are also new highly purified factor VIII concentrates coming

out on the market which are expected to be much safer in comparison to older concentrates as regards the risk for virus transmission. However, no guarantees on the absence of virus can be made. Furthermore, the concentrates are fairly expensive because the raw material plasma is expensive due to limited supply.
A recombinant factor VIII is likely to solve a large extent of the problems associated with the use of plasma derived factor VIII concentrates. In view of the need of a recombinant factor VIII for the treatment of hemophilia A, a couple of groups are presently working on the development of such a product. However, the development of a recombinant factor VIII has met some difficulties. One of the major problems is to produce recombinant factor VIII in sufficiently high yields. Most of the development work done has been performed with use of the cDNA gene coding for the full-length factor VIII molecule.
This invention describes a deleted factor VIII cDNA which codes for a recombinant factor VIII derivative, corre- sponding, as regards to molecular weight and other biochemical characteristics, to a previously described plasma factor VIII form present in considerable amounts in commercial concentrates (Anderson, L-O. et al (1986), Proc. Natl. Acad. Sci. USA 83, 2979-2983). The expression level obtained upon expressing this molecule in an animal cell culture has proven to be considerably higher as compared to when the full-length factor VIII cDNA is used to express factor VIII. The new deleted factor VIII cDNA is likely to give sufficiently high yields of recombinant factor VIII to be used in an industrial process for a pharmaceutical preparation of recombinant factor VIII.
DEFINITIONS USED
In the following sections, the nomenclature of the different structural domains of the 2332 amino acid single stranded full-length factor VIII is similar to those defined

by Vehar, GA. et al (1984), Nature 312, 337-342. Accordingly, the A1 and A2 domains are contained within the factor VIII heavy chain form of approximately 200 kDa (amino acids 1 through 1648) to approximately 90 kDa (amino acids 1 through . 740). The A3, C1 and C2 domains are contained within the factor VIII light chain of approximately 80 kDa (amino acids 1649 through 2332). The B domain constitutes the heavily glycosylated middle region of full-length single chain factor VIII or the C-terminal part of the 200 kDa form of the factor VIII heavy chain (amino acids 741 through 1648). The term
«factor. VIII deletion derivative» is defined as one or more polypeptide chains having factor VIII:C activity derived from the full-length factor VIII polypeptide by deleting one or more amino acids. The term «factor VIII:QD» is defined as a polypeptide chain derived from full-length factor VIII lacking amino acids 745 through 1562. The term «factor VIII:RE» is defined as a polypeptide chain derived from full-length factor VIII lacking amino acids 741 through 1648. The term factor VIII:SQ is defined as a polypeptide chain derived from full-length factor VIII lacking amino acids 743 through 1636.
PRIOR ART
In fresh plasma prepared in the presence of protease inhibitors, factor VIII has been shown to have a molecular weight of 280 kDa and to be composed of two peptide chains with molecular weights of 200 kDa and 80 kDa, respectively (Andersson, L-O et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2979-2983). These chains are held together by metal ion bridges. More or less proteolyt ically degraded forms of the factor VIII molecule were found as active fragments in factor
VIII material purified from commercial concentrates (Andersson, L-O et al. 1986; Andersson, et al. (1985) EP 0197901). The fragmented forms of factor VIII having molecular weights from 260 kDa down to 170 kDa, consisted of one heavy chain with a molecular weight ranging from 180 kDa down to 90 kDa (all variants having the identical N-termini) in combination

with the 80 kDa light chain. The N-terminal region of the heavy chains is identical to that of the single chain factor VIII obtained from the nucleotide sequence data of the factor VIII cDNA (Wood, W.I., et al. (1984) Nature 312, 330-336, Vehar, G.A., et al., (1984) Nature 312, 337342).
The smallest active form, with molecular weight 170 kDa, containing one 90 kDa and one 80 kDa chain could be activated with thrombin to the same extent as the higher molecular forms. It thus represents an unactivated form. It has also been shown to have full biological activity in vivo as tested in hemophilia dogs (Brinkhous, K.M. et al. (1985)
Proc .Natl .Acad.Sci. USA 82, 8752-8756). Thus, the haemostatic effectiveness was the same as for the high molecular weight forms of factor VIII. Furthermore, there was an indication that the 170 kDa form had an in vivo survival time that was
50% longer as compared to that of the higher molecular forms.
The fact that the middle heavily glycosylated part of the factor VIII polypeptide chain residing between amino acids Arg-739 and Glu-1649 does not seem to be necessary for full biological activity has prompted several researchers to attempt to produce derivatives of recombinant factor VIII lacking this region. This has been achieved by deleting a portion of the cDNA encoding the.middle heavily glycosylated part of factor VIII either entirely or partially.
For example, J.J. Toole, et al. reported the construction and expression of factor VIII lacking amino acids 982 through 1562, and 760 through 1639, respectively (Proc. Natl. Acad.Sci. USA (1986) 83, 5939-5942). D.L. Eaton et al. reported the construction and expression of factor VIII lacking amino acids 797 through 1562 (Biochemistry (1986) 25, 8343- -8347). R.J. Kaufman described the expression of factor VIII lacking amino acids 741 through 1646 (PCT application No. WO 87/04187). N. Sarver et al. reported the construction and expression of factor VIII lacking amino acids 747 through 1560 (DNA (1987) 6, 553-564). M. Pasek reported the construction and expression of factor VIII lacking amino acids 745

through 1562, and amino acids 741 through 1648, respectively (PCT application No. 88/00831). K-D Langner reported the construction and expression of factor VIII lacking amino acids. 816 through 1598, and amino acids 741 through 1689, respectively (Behring Inst. Mitt., (1988) No 82, 16-25, EP 295
597). P. Meulien, et al., reported the construction and expression of Factor VIII lacking amino acids 868 through 1562, and amino acids 771. through 1666, respectively (Protein Engineering (1988) 2 (4), 301-306, EP 0 303 540 A1). When expressing these deleted forms of factor VIII cDNA in mammalian cells the production level is typically 10 times higher as compared to full-length factor VIII.
Furthermore, attempts have been made to express the 90 kDa and 80 kDa chains separately from two different cDNA derivatives in the same cell (Burke, R.L. et al. (1986),
J.Biol.Chem. 261, 12574-12578, Pavirani, A. et al. (1987) Biochem. Biophys. Res. Cornm., 145, 234-240). However, in this system the in vivo reconstitution seems to be of limited efficiency in terms of recovered factor VIII:C activity.
DESCRIPTION OF THE INVENTION
The present invention deals with processes for production of proteins consisting of one or more polypeptide chains having factor VIII:C activity. More specifically, the present invention provides a modified cDNA sequence derived from the full-length factor VIII cDNA, which upon expression in animal cells gives rise to the high level production of a protein with factor VIII:C activity consisting essentially of two polypeptide chains of 90 kDa and 80 kDa molecular weight, respectively.
Accordingly, the present invention provides for a DNA sequence coding for a biologically active recombinant human factor VIII derivative, comprising a first DNA segment coding for the 90 kDa ‘chain of human factor VIII and a second DNA segment coding for the 80 kDa chain of human factor VIII said segment being interconnected by a linker DNA segment coding

for a linker peptide of 4 to about 100 amino acid residues of the B domain of human factor VIII, at least 4 of said amino acid residues originating from the C terminal of said domain.
It is preferred that said linker codes for at least 4 amino acid residues originating from the C terminal of the B domain of human factor VIII. In a preferred embodiment of the invention said linker gene codes for up to about 20 amino acid residues of the B domain of human factor VIII.
In a particularly preferred embodiment of the invention said DNA sequence contains a linker coding for an amino acid sequence comprising 12 amino acids originating from the B domain of human factor VIII.
As a preferred example said linker may code for at least 7 amino acid residues of the B domain of human factor VIII, at least 7 amino acid residues originating from the C terminal and at least 2 amino acid residues originating from the N terminal of said domain.
In a specific embodiment of the present invention the DNA sequence contains a linker coding for 12 amino acid residues originating from the C terminal and 2 amino acid residues originating from the N terminal of the B domain of human factor VIII.
The invention also relates to a recombinant expression vector containing a transcription unit comprising the DNA sequence as outlined above and, furthermore, a promoter and a polyadenylation signal sequence.
The invention also covers host cells of animal origin transformed with the recombinant expression vector as define above.
Additionally, the invention provides for a process fo the manufacture of a biologically active recombinant human factor VIII derivative as described above, said process comprising cultivating an animal cell line transformed with a recombinant expression vector as defined above in a nutrient medium allowing expression and secretion of human factor VII derivative composed of the 90 kDa domain and, linked thereto

by metal ion bond, the 80 kDa domain, said expressed derivative being then recovered from the culture medium.
Finally, the invention provides for a human factor VIII derivative comprising the 90 kDa domain and, linked thereto, optionally via the linker peptide or part thereof, by metal ion bond, the 80 kDa domain of human factor VIII.
In order to obtain a protein with factor VIII:C activity consisting of the above two polypeptide chains, the single polypeptide chain created during translation in vivo has to be cleaved either by post-translat ional processing in the producing cell or by proteolytic processing in vitro. or both. Since protein with factor VIII activity, consisting of the two polypeptide chains of 200 kDa and 80 kDa molecular weight, can be isolated from human plasma, it is assumed that there exists an appropriate cleavage site for processing enzymes, according to the above, on the single chain full- -length factor VIII primary translation product. Most probably, an important in vivo processing site is located at the carboxy-terminal side of Arg-1648. During maturation, cleavage at Arg-1648 gives rise to a factor VIII protein consisting of two chains of molecular weights of 200 kDa and 80 kDa. Since Arg-1648 seems to be located at a border between structural domains in the factor VIII molecule, it constitutes a sterically accessible target for the processing enzyme or enzymes. Conceivably, there exists another processing site, at Arg-740 which will give rise to conversion of the 200 kDa chain to a 90 kDa chain in vitro, thus creating the 90 kDa and 80 kDa form of factor VIII present in commercial human plasma derived factor VIII concentrates. In accordance with the present invention it has been found that in order to produce a factor VIII deletion derivative that can be processed either in vivo or in vitro. or both, to a two chain protein consisting of polypeptide chains of 90 kDa and 80 kDa, the amino acid sequences surrounding Arg-740 and Arg-1648 have to be conserved in order to preserve the structural requirements for correct cleavage. More specifically, if for example amino

acids 743. through 1636 of the full-length factor VIII polypeptide are deleted, a new polypeptide chain is obtained where there are 14 amino acids linking Arg-740 and Arg-1648. Of these 14 amino acids, the sequence of the five amino-terminal ones directly corresponds to the five amino acids following
Arg-740 in full-length factor VIII. Also, the sequence of the 12 carboxy-terminal amino acids of the above 14 amino acid fragment directly corresponds to the 12 amino acids preceding Glu-1649 in full-length factor VIII thus creating a 3 amino acid overlap between the N- and C-terminal regions of the B- domain.
In order to produce a factor VIII:SQ protein at high level consisting of two polypeptide chains according to the above, the cDNA encoding this factor VIII deletion derivative is assembled into an efficient transcriptional unit together with suitable regulatory elements in a cloning vector, that can be propagated in E. coli according to methods known to those skilled in the art. Efficient transcriptional regulatory elements could be derived from the chromosomal DNA of eucaryotic cells. For instance, promoter-enhancer combinations from strongly constitutively transcribed genes can be used, preferably metallothionein, beta-actin or GRP78. Also, efficient transcriptional regulatory elements can be derived from viruses having eukaryotic cells as their natural hosts. For instance, promoter-enhancer combinations derived from viruses residing on animal hosts can be used, preferably the enhancer and promoter occurring in Rous sarcoma virus long terminal repeat, simian virus 40, the adenovirus major late promoter, and the human .cytomegalovirus immediate early promoter. In order to obtain stable high level amounts of mRNA transcribed from the factor VIII:SQ cDNA, the transcriptional unit should contain in its 3′-proximal part a DNA region encoding a transcriptional termination-polyadenylation sequence. Preferably, this sequence is derived from the Simian Virus 40 early transcriptional region or the rabbit beta-globin gene.

The factor VIII:SQ cDNA assembled into an efficient transcription unit is then introduced into a suitable host organism for expression of the factor VIII:SQ protein. Preferably this organism should be an animal cell-line of vertebrate origin in order to ensure correct folding, disulfide bond formation and secretion as well as other post-translational modifications. Examples of the latter are asparagine-linked glycosy lation, tyrosine O-sulfatation, and proteolytic processing of the nascent single polypeptide chain which is essential for the formation of the 90 kDa and 80 kDa two chain factor VIII protein. Examples of cell-lines that can be used are moneky COS-cells, mouse L-cells, mouse C127-cells, hamster BHK-21 cells, and preferentially CHO-cells.
The transcription unit encoding the factor VIII:SQ cDNA can be introduced into an animal cell-line in several different ways. One example of this is to create recombinants between the above transcription unit and vectors based on different animal viruses. Examples of these are vectors based on vaccinia virus, SV40 virus, and preferably bovine papilloma virus.
The transcription unit encoding the factor VIII:SQ cDNA can also be introduced into an animal cell-line together with another recombinant gene which may function as a dominant selectable marker in these cells in order to facilitate the isolation of specific cell clones which have integrated the recombinant DNA into the genome. Examples of this type of dominant selectable marker genes are Tn5 aminoglycoside phosphotransf erase (resistance to Geneticin, G418), and puromycin acetyltransf erase (resistance to puromycin). The transcription unit encoding such a selectable marker gene can reside either on the same vector as the one encoding the factor VIII:SQ unit. It can also be encoded on a separate vector which is simultaneously introduced and integrated into the genome of the host cell, frequently resulting in tight physical linkage between the different transcription units.
Other types of dominant selectable marker genes which

can be used together with the factor VIII:SQ cDNA are based on various transcription units encoding dihydrof olate reductaεe (dhfr). After introduction of this type of gene into cells lacking endogenous dhfr-activity, preferentially CHO- -cells (DUKX-B11, DG-44) it will enable these to grow in medium lacking nucleosides. An example of such a medium is Ham’s F12 without hypoxanthin, thymidin, and glycine. These dhfr-genes can be used in conjunction with the factor VIII:SQ transcriptional unit in CHO-cells of the above type, either linked on the same vector or in two different vectors, thus creating dhfr-positive cell-lines producing recombinant factor VIII:SQ protein.
If the above cell-lines are grown in the presence of the cytotoxic dhfr-inhibitor methotrexate, new cell-lines resistant to methotrexate will emerge. These cell-lines may produce recombinant factor VIII:SQ protein at an increased rate due to the amplified number of linked dhfr and factor VIII:SQ transcriptional units. When propagating these cell- lines in increasing concentrations of methotrexate (1-10000 nM), new cell-lines can be obtained which produce the factor VIII:SQ protein at very high rate.
The above cell-lines producing factor VIll:SQ protein can be grown in a large scale, either in suspension culture or on various solid supports. Examples of these supports are microcarriers based on dextran or collagen matrices, or solid supports in the form of hollow fibers or various ceramic materials. When grown in suspension culture or on microcarriers the culture of the above cell-lines can be performed either as a batch culture or as a perfusion culture with continuous production of conditioned medium over extended periods of time. Thus, according to the present invention, the above cell-lines are well suited for the development of an industrial process for the production of recombinant factor
VIII-SQ which corresponds to the authentic two polypeptide chain factor VIII (90 kDa and 80 kDa) that can be isolated from human plasma.

The recombinant factor VIII:SQ protein which accumulates in the medium of CHO-cells of the above type, can be concentrated and purified by a variety of biochemical methods, including methods utilizing differences in size, charge, solubility, hydrophobicity, specific affinity, etc. between the recombinant factor VIII:SQ and other substances in the conditioned medium.
An example of such a purification is the adsorption of the recombinant factor VIII:SQ protein to a monoclonal anti- body which is immobilised on a solid support. After desorption, the factor VIII:SQ protein can be further purified by a variety of chromatographic techniques based on the above properties.
The protein with factor VIII activity described in this invention can be formulated into pharmaceutical preparations for therapeutic use. The produced recombinant factor VIII:SQ protein may be dissolved in conventional physiologically compatible aqueous buffer solutions to which there may be added, optionally, pharmaceutical adjuvants to provide pharmaceutical preparations.
The present invention will be further described more in detail in the following by non-limiting examples thereof. This description of specific embodiments of the invention will be made in conjunction with the appended drawings, wherein:
Figure 1 is a schematic representation of the relationship between full-length factor VIII and factor VIII:SQ. The primary structure of the region between the C-terminus of the 90 kDa chain and the N-terminus of the 80 kDa chain is shown. The vertical arrow indicates the peptide bond that is cleaved to give the two-chain product;
Figure 2 is an illustration of plaεmid pKGE436 containing the factor VIII:SQ cDNA under transcriptional control of the human cytomegalovirus promoter;
Figure 3 is an illustration of plasmid pKGE327 containing the mouse dihydrof olate reductase cDNA under transcrip

tional control of the mouse mammary tumor virus long terminal repeat;
Figure 4 is an illustration of immuno-blotting of recombinant factor VIII SQ after polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate;
Figure 5 shows a diagram on changes in factor VIII activity of recombinant factor VIII:SQ following incubation with thrombin; and
Figure 6 illustrates changes in patterns of SDS-PAGE and immunoblotting of recombinant factor VIII:SQ following incubation with human α-thrombin.
EXAMPLE 1
A deletion derivative of factor VIII cDNA has been constructed that encodes a polypeptide chain devoid of most of the B-domain, but containing parts of the amino-terminal and carboxy-terminal sequences of the B-domain that are essential for in vivo proteolytic processing of the primary translation product into two polypeptide chains.
Mutaαeneεiε of factor VIII cDNA.
A 894 base-pair Kpnl-Pstl restriction fragment obtained from the cDNA of the factor VIII:QD deletion derivative (M. Pasek, PCT application No. WO88/00831) encoding the amino acids Leu 587 through Ala 1702 was introduced into the bacteriophage vector M13mpl9 ( Yanisch-Ferron, C. et al. (1985) Gene 33, 103-119) according to the standard methods of the art. The resulting recombinant phage clone was used as source for preparation of single stranded DNA used as template for oligonucleotide directed mutagenesis (Nakamaye, K. and Eckstein, F. (1986) Nucleic Acidε Res. 14, 9679-9698). 10μg purified circular single stranded vector DNA was annealed to 8 pmoles of a 5′-phosphorylated oligonucleotide with the following sequence:
5′-GCCATTGAACCAAGAAGCTTCTCTCAGAATCCACCAGTCTTGAAACGC-3

The second strand of circular DNA was syntheεised on the resulting template by addition of all four deoxynucleotides, dCTPαS, 12 units of Klenow fragment of DNA-polymerase I, and 12 unite of T4 DNA-ligase. After overnight incubation at 16°C, the reaction mixture was enriched for double stranded DNA by filtering through nitrocellulose in the presence of 500 mM NaCl. One fifth of the purified double stranded DNA was nicked by incubation with 5 units of the restriction enzyme Neil, treated by 50 units of Exonuclease III to such. an extent that the template strand of the phage DNA was partially removed. The resulting partial duplex was reconverted to double stranded DNA by treatment with 3 unitε DNA polymerase I and 2 units T4 DNA-ligase in the presence of all four deoxynucleot ide tr iphoεphateε at 16°C for 3 hours. One fourth of the resulting mixture was uεed to transform 300 μl E.coli TGI. Of the resulting mutagenised phage clones, ten were subjected to dideoxy sequencing (Sanger, F. et al. 1977, Proc. Natl. Acad. Sci. USA 74, 5463-5467). One of the resulting phage clones showed the expected nucleotide sequence indicating that a 228 base-pair segment had been removed which corresponds to amino acids Asp 1563 through Ser 1637 of factor VIII:QD. This creates a novel 666 base-pair Kpnl-Pstl fragment of the factor VIII cDNA within the M13mpl9 vector encoding a fusion between Phe 742 and Ser 1637 of the factor VIII protein (factor VIII:SQ).
Construction of a Mammalian Expression Vector Encoding factor VIII :SQ.
The 666 base-pair Kpnl-Pstl fragment encoding the factor VIII:SQ fusion according to the above was isolated from the double stranded replicative form of the M13mp19 phage DNA and introduced into the vector pKGE431. This vector consists of a 2046 base-pair Kpnl-Sphl fragment from the factor
VIII:RE cDNA (M. Pasek, PCT application No. WO88/00831, ATCC accession No. 53517) encoding amino acids Leu 587 through Met 2176 of the factor VIII:RE protein in pUC19. In order to ac

commodate the factor VIII:SQ 666 base-pair Kpnl-Pstl fragment in a desired manner the pKGE431 DNA had to be opened by complete Kpnl digestion and partial Pstl digestion. The fragment of pKGE431 in which Pstl cleaved in a position corresponding to Ala 1702 in the factor VIII:RE protein was isolated and ligated to the above Kpnl-Pstl fragment of the factor VIII:SQ cDNA creating the vector pKGE432. The latter vector was digested with Kpnl and Apal and the corresponding 1700 base- -pair Kpnl-Apal fragment encoding Leu 587 through Ala 2047. of the factor VIII:SQ protein waε ligated to the large fragment of the vector pKGE347 that had been digested with Kpnl and Apal. The vector pKGE347, which is based on the E. coli cloning vector pBR327, consists of the human cytomegalovirus enhancer/promoter encoded on a 741 base-pair DNA-segment (nucleotide positions – 671 to +71, Boshart, M. et al (1985) Cell 41, 521-530) upstream of the factor VIII:QD cDNA with the SV40 t-antigen intron and polyadenylation sequence at the 3′-proximal part. The resulting vector (pKGE436), which is depicted in Figure 2, contains the complete factor VIII:SQ cDNA and is identical to pKGE347 except for the different deletion derivative of factor VIII that is encoded.
EXAMPLE 2
Transfection of Chinese Hamster Ovarv Cells.
In a 10 centimeter diameter cell culture dish, 0.5 million dihydrof olate reductase deficient Chinese Hamster Ovary Cells (CHO-DG44, obtained from Dr. L.A. Chasi-n, Columbia University, New York) were seeded in Dulbecco’s Modified Eagles Medium/Ham’s F12 (1:1) supplemented by 10% foetal calf serum and incubated over night at 37°C in a 5% carbon dioxide incubator. The next day the cells were washed with fresh medium and subsequently transfected by the calcium phosphate method with 10 μg of a.1:1 mixture of the factor VIII:SQ expression vector pKGE436 and the dihydrofolate reductase vector pKGE327 according to the methods of the art. The vector pKGE327 contains a transcription unit consisting of the mouse

mammary tumor virus long terminal repeat upstream of the mouse dihydrof olate reductase cDNA with the SV40 t-antigen and polyadenylation sequence at the 3’-proximal part cloned into the vector pML2 in a clockwise manner (Figure 3). On day three, the medium was removed, the cells washed and split into new cell cultivation diεheε. On day four, the selection for dihydrof olate reductase positive cells was initiated by replacing the media with the above cell cultivation medium lacking hypoxanthin, glycin, and thymidin and supplemented with 10% thoroughly dialyzed foetal calf εerum. The medium was changed twice a week and after approximately two weeks colonies of dihydrof olate redμctase positive cells could be harvested. These colonies were further grown in 25 cm2 cell culture bottles, and after reaching subconf luency the medium was replaced with fresh medium containing 3% foetal calf serum. After a period of 24 hours the activity of the factor VIII:C in the culture medium was tested using the synthetic substrate method (Coatest factor VIII:C, KABI). The results are shown below in Table 1.

Gene Amplification of CHO-DG44 Cell Lines Producing factor VIII:SQ
The CHO-DG44 cell line 208:22 in Table 1 producing 467 mU/ml/day of factor VIII:SQ was chosen for further gene amplification by selection and growth in methotrexate. After several weeks of cultivation in 20 nM methotrexate the cell line 208:22 gave rise to several new resistant. cell clones. These clones were harvested individually and further expanded as separate cultures as described above. The productivity of factor VIII:C in the medium of these clones were assayed as in Example 1. The result is shown in Table 2.

EXAMPLE 3
Purification and Biochemical Characterization of factor VIII:SQ
Factor VIII:SQ produced by the amplified CHO-DG44 cell-line 208:22 was examined for biochemical characteris

tics. A partial purification of the factor VIII material from culture medium was performed prior to the study. This included an immunoaf f inity chromatography step with the use of a matrix containing monoclonal antibodies directed against factor VIII followed by an ion-exchange chromatography step. The specific activity of the purified factor VIII material obtained was in the range of 3000-4000 IU/A280 and the ratio factor VIII activity/factor VIII antigen was close to 1 (activity was measured with Coatest (KABI), and antigen was determined by an Elisa assay with use of monoclonal antibodies directed against the 80 kDa chain). The purified factor VIII:SQ material was submitted to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. The SDS-PAGE was carried out according to Laemmli (1970) Nature 227, 680-685. Rabitt polyclonal anti-human factor VIII antibodies were used for the Western blot analysis and the analysiε waε essentially performed as described by Towbin, H. et al. (1979) Proc. Natl. Acad. Sci. USA, 76, 4350-4354. The results obtained are shown in Fig. 4, Lane 1: plasma factor VIII containing an 80 kDa light chain and heavy chains ranging from 200 kDa to 90 kDa. Lanes 2 and 3: recombinant factor VIII:SQ containing an 80 kDa chain and a 90 kDa chain. The materials originated from two different batches factor VIII:SQ purified as described above. The analysis thus showed the preεence of two major bands in the factor VIII SQ material; one at 90 kDa and one doublet band at 80 kDa. The two bands were found in the same position on the gel as the 90 kDa and 80 kDa peptides representing the smallest biologically active complex of plasma factor VIII. A minor amount of a 170 kDa band (< of 5% of the total material) was also found in the factor VIII:SQ material, probably repre sent ing unc l eaved pr imary t rans lat i on product . Furthermore, N-terminal sequence determination with automated Edman degradation of the factor VIII:SQ protein, indicated that the N-termini of the 90 kDa and 80 kDa chains are identical to those of plasma derived 90 kDa plus 80 kDa factor VIII. This result thus showed that the in vivo proteo lytic processing of the primary translation product into two polypeptide chains had been effective. Factor VIII:SQ could be activated by human thrombin in a dose dependent manner. Inactivation was subsequently followed. In Figure 5, the curve of .activity changes obtained is shown when 0.1 U thrombin per 1 IU purified factor VIII:SQ was added. A one-stage clotting method (Mikaelsson, M. et al. (1983) Blood 62, 1006-1015) was used for immediate assay of samples from the reaction mixture. A fifteen-fold activation was obtained whithin one minute, which then was followed by inactivation. Sodium dodecyl sulfate at 0.02 g/ml was added to stop the reaction in samples for analysis. SDS-Poly- acrylamide gel electrophoresis and Western blot analysis with rabbit polyclonal antibodies against human factor VIII was performed on samples taken out at time intervals during the reaction (Figure 6). Electrophoresis and immunoblotting were performed as described in relation to Figure 4. The reεultε obtained showed a molecular change of factor VIII peptides identical to that of plasma factor VIII during incubation with thrombin. Thus the 90 kDa peptide was cleaved by thrombin and a 50 kDa plus a 40 kDa peptide was formed. The 80 kDa peptide was cleaved and a 70 kDa peptide was formed. The weak band seen at 170 kDa in the factor VIII:SQ sample disappeared during the first minute of incubation with thrombin, and peptides were apparently formed identical to those formed from the 90 kDa-80 kDa complex. The studies with thrombin showed that factor VIII:SQ behaves as plasma factor VIII in the interaction with this enzyme. This feature is regarded to be essential for biological activity in vivo. The interaction of factor VIII:SQ with human von Willebrand factor was studied with the use of size-exclusion chromatography on Sepharόse CL-6B. Ten (10)IU of factor VIII:SQ was incubated with 30 U purified human von Willebrand factor at 37°C for 20 minutes. The incubation mixture was then applied on a column packed with Sepharose CL-6B. All material with factor VIII activity eluted in the void volume with von Willebrand factor. When factor VIII:SQ with no added von Willebrand factor was applied on the column, material with factor VIII activity eluted only in the inner fractions at a position where also the 90 kDa-80 kDa form of plasma factor VIII eluted. This result showε that factor VIII:SQ has the capacity to bind to von Willebrand factor, which is a property necessary for good in vivo survival (Brinkhous, K.M. et al. (1985) Proc. Natl. Acad. Sci. USA 82, 8752-8756). The factor VIII:SQ DNA of the present invention has been depoεited with Deutsche Sammlung von Mikroorganismen und Zellkulturen on December 13, 1989 and has been given the deposition number DSM 5693. Claims (11) CLAI MS 1. A DNA sequence coding for a biologically active recombinant human factor VIII derivative, comprising a first DNA segment coding for the 90 kDa chain of human factor VIII and a second DNA segment coding for the 80 kDa chain of. human factor VIII, said segments being interconnected by a linker DNA segment coding for a linker peptide of 4 to about 100 amino acid residues of the B domain of human factor VIII, at least 4 of said amino acid residues originating from the C terminal of said domain. 2. A DNA sequence according to claim 1, wherein said linker codes for at least 4 amino acid residues originating from the C terminal of the B domain, of human factor VIII. 3. A DNA sequence according to claim 1 or 2, wherein said linker gene codes for up to about 20 amino acid residues of the B domain of human factor VIII. 4. A DNA sequence according to claim 1, 2 or 3, wherein said linker codes for an amino acid sequence comprising 12 amino acids originating from the B domain of human factor VIII. 5. A DNA sequence according to any preceding claim, wherein said linker codes for at least 7 amino acid residues of the B domain of human factor VIII, at least 4 amino acid residues originating from the C terminal and at least 2 amino acid residues from the N terminal of said domain. 6. A DNA sequence according to any preceding claim, wherein said linker codes for 12 amino acid residues originating from the C-terminal and 2 amino acid residues originating from the N-terminal of the B domain of human factor VIII. 7. A recombinant expression vector containing a transscription unit comprising the DNA sequence according to any of claims 1 to 5, a promoter and a polyadenylation signal sequence. 8. A host cell of animal origin transformed with the recombinant expression vector of claim 7. 9. A process for the manufacture of a biologically active recombinant human factor VIII derivative expressed by a DNA sequence according to any of claims 1 to 6, characterized by cultivating an animal cell line transformed with a recombinant expression vector according to claim 7 in a nutrient medium allowing expression and secretion of human factor VIII derivative composed of two polypeptides with molecule weights of 90 kDa and 80 kDa, respectively, linked to each other by a metal ion bridge, and recovering said derivative from the culture medium. 10. The human factor VIII derivative whenever prepared by the process of claim 9. 11. The human factor VIII derivative of claim 10, comprising the 90 kDa domain and, linked thereto optionally via the linker peptide or part thereof, by metal ion bond, the 80 kDa domain of human factor VIII. AU70393/91A 1989-12-15 1990-12-06 A recombinant human factor VIII derivative Expired AU645539B2 (en) Applications Claiming Priority (2) Application Number Priority Date Filing Date Title SE8904239 1989-12-15 SE8904239A SE465222C5 (en) 1989-12-15 1989-12-15 A recombinant human factor VIII derivative and process for its preparation Publications (2) Publication Number Publication Date AU7039391A true AU7039391A (en) 1991-07-18 AU645539B2 AU645539B2 (en) 1994-01-20 Family ID=20377785 Family Applications (1) Application Number Title Priority Date Filing Date AU70393/91A Expired AU645539B2 (en) 1989-12-15 1990-12-06 A recombinant human factor VIII derivative Country Status (21) Country Link EP (3) EP0506757B2 (en) JP (1) JP2644084B2 (en) AT (2) ATE170219T1 (en) AU (1) AU645539B2 (en) BR (1) BR9007921A (en) CA (1) CA2071875C (en) DE (3) DE69034040T2 (en) DK (2) DK0786474T3 (en) ES (2) ES2119769T5 (en) FI (1) FI104260B (en) HK (2) HK1019449A1 (en) HU (1) HU211504A9 (en) IE (1) IE904510A1 (en) LU (1) LU90457I2 (en) NL (1) NL990035I2 (en) NO (1) NO309041B1 (en) NZ (1) NZ236276A (en) PT (1) PT96208B (en) SE (1) SE465222C5 (en) SG (1) SG66753A1 (en) WO (1) WO1991009122A1 (en) Families Citing this family (136) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations SE468050C (en) * 1991-03-15 1998-02-11 Pharmacia & Upjohn Ab Recombinant human factor VIII derivative US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII DK53792D0 (en) * 1992-04-24 1992-04-24 Novo Nordisk As PROCEDURE FOR PRODUCING PROTEINS DK0627924T3 (en) * 1992-10-02 2001-04-30 Genetics Inst Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer SE9300509D0 (en) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab PEG TREATMENT SE9301581D0 (en) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab PROTEIN FORMULATION SE504074C2 (en) * 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration SE9303601D0 (en) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration SE503424C2 (en) * 1994-11-14 1996-06-10 Pharmacia Ab Process for purification of recombinant coagulation factor VIII SE9403915D0 (en) * 1994-11-14 1994-11-14 Annelie Almstedt Process A US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders SE9501189D0 (en) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation WO1997003193A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties SE9503380D0 (en) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives EP1318198B1 (en) * 1996-05-14 2006-03-22 Biovitrum Ab Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same CA2312291A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations SE9901379D0 (en) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures AT409379B (en) 1999-06-02 2002-07-25 Baxter Ag MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE US7572619B2 (en) * 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII AU2003249990B2 (en) 2002-07-09 2007-06-28 Takeda Pharmaceutical Company Limited Animal protein free media for cultivation of cells HUE058897T2 (en) 2003-02-26 2022-09-28 Nektar Therapeutics Polymer-factor viii moiety conjugates CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates CA3072423A1 (en) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin PL2586456T3 (en) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling and glycopegylation of fibroblast growth factor (FGF) US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells PL2363414T3 (en) 2004-11-12 2022-09-05 Bayer Healthcare Llc Site-directed modification of FVIII CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins EP1866422B1 (en) 2005-04-07 2016-04-06 The Trustees of The University of Pennsylvania Method of increasing the function of an aav vector EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii CN101516388B (en) 2006-07-21 2012-10-31 诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life ES2651028T3 (en) 2007-02-23 2018-01-23 Sk Chemicals Co., Ltd. Process to produce and purify factor VIII and its derivatives NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars NZ586250A (en) 2007-12-27 2012-11-30 Baxter Int Cell culture processes RU2573587C2 (en) 2008-02-27 2016-01-20 Ново Нордиск А/С Conjugated factor viii molecules BRPI1008061B1 (en) 2009-02-03 2022-01-25 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides (xten), isolated fusion protein comprising the same and method of improving a property of a biologically active protein ME02979B (en) 2009-06-09 2018-10-20 Prolong Pharmaceuticals Llc Hemoglobin compositions US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates CN104530182A (en) 2009-07-27 2015-04-22 利普森技术有限公司 Glycopolysialylation of non-blood coagulation proteins RU2533619C2 (en) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Glycopolysialylation of proteins, which are not blood clotting proteins US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage JP2013502458A (en) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド Coagulation factor VII composition and methods of making and using the same GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111 MY159135A (en) 2009-12-06 2016-12-15 Biogen Idec Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins SG10201502270TA (en) 2010-03-29 2015-05-28 Univ Pennsylvania Pharmacologically induced transgene ablation system US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system EP2591099B1 (en) 2010-07-09 2020-11-18 Bioverativ Therapeutics Inc. Chimeric clotting factors EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof WO2012035050A2 (en) 2010-09-15 2012-03-22 Novo Nordisk A/S Factor viii variants having a decreased cellular uptake DK2654794T3 (en) 2010-12-22 2020-06-08 Baxalta GmbH MATERIALS AND PROCEDURES FOR CONJUGING A WATER SOLUBLE FAT ACID DERIVATIVE TO A PROTEIN TR201908020T4 (en) 2011-02-17 2019-06-21 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer. EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof CN103796670A (en) 2011-07-08 2014-05-14 比奥根艾迪克依蒙菲利亚公司 Factor VIII chimeric and hybrid polypeptides, and methods of use thereof WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii TR201816253T4 (en) 2012-01-12 2018-11-21 Bioverativ Therapeutics Inc Methods for reducing immunogenicity against factor VIII in subjects receiving factor VIII therapy. EA035323B1 (en) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Chimeric factor viii polypeptides and uses thereof KR102097263B1 (en) 2012-02-15 2020-04-06 바이오버라티브 테라퓨틱스 인크. Factor viii compositions and methods of making and using same KR102008190B1 (en) 2012-02-15 2019-08-07 바이오버라티브 테라퓨틱스 인크. Recombinant factor viii proteins EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof NZ703366A (en) 2012-07-11 2018-03-23 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof RU2500818C1 (en) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") RECOMBINANT PLASMID DNA pAP227 CODING POLYPEPTIDE OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, LINE OF CELLS Cricetulus griseus CHO, 2H5-PRODUCER OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, AND METHOD FOR OBTAINING POLYPEPTIDE HAVING ACTIVITY OF RECOMBINANT FACTOR VIII EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide SI2956477T1 (en) 2013-02-15 2021-03-31 Bioverativ Therapeutics Inc. Optimized factor viii gene SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations WO2014144795A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor viii polypeptide formulations US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins TWI667255B (en) 2013-08-14 2019-08-01 美商生物化學醫療公司 Factor viii-xten fusions and uses thereof US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods BR112016009064A2 (en) 2013-10-22 2017-09-19 Inst Nat Sante Rech Med CUTANEOUS PATTER DEVICE; DRUG RELEASE SYSTEM; KIT; AND METHOD OF TREATMENT OF HEMOPHILIA IN AN INDIVIDUAL IN NEED OF THE SAME US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof DK3080274T3 (en) 2013-12-09 2020-08-31 Sangamo Therapeutics Inc Methods and compositions for genome manipulation SI3091997T1 (en) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof KR102567586B1 (en) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications WO2016012595A1 (en) * 2014-07-25 2016-01-28 Csl Behring Gmbh Improved factor viii preparations suitable for therapeutic use and processes to obtain these MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES WO2016168728A2 (en) 2015-04-16 2016-10-20 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same US11753461B2 (en) 2016-02-01 2023-09-12 Bioverativ Therapeutics Inc. Optimized factor VIII genes US20200085915A1 (en) 2016-12-02 2020-03-19 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors AU2017366709A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors KR20200035130A (en) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and uses thereof CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells EP3746136A1 (en) 2018-02-01 2020-12-09 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii WO2019195055A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A KR20210042128A (en) 2018-08-09 2021-04-16 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and their use for nonviral gene therapy UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density CN116209430A (en) 2020-08-07 2023-06-02 阿米库斯治疗学公司 Vesicle targeting proteins and uses thereof US20230084036A1 (en) 2021-08-23 2023-03-16 Bioverativ Therapeutics Inc. Optimized factor viii genes WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity Family Cites Families (7) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title KR910006424B1 (en) * 1985-08-21 1991-08-24 인코텍스 비.브이 Method of manufacturing knitted briefs WO1987004187A1 (en) * 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS EP0251843A1 (en) * 1986-06-06 1988-01-07 Transgene S.A. Process for the preparation of factor VIII from mammalian cells JPH0637425B2 (en) * 1986-11-11 1994-05-18 株式会社クラレ Method for producing high boiling point (meth) acrylic acid ester FR2619314B1 (en) * 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME JP2586092B2 (en) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 Method for producing polyfunctional (meth) acrylate HUT64591A (en) * 1989-11-17 1994-01-28 Novo Nordisk As Protein complexes with viii/c factor activity and process for their production 1989 1989-12-15 SE SE8904239A patent/SE465222C5/en not_active Application Discontinuation 1990 1990-11-29 NZ NZ236276A patent/NZ236276A/en unknown 1990-12-06 AT AT91901327T patent/ATE170219T1/en active 1990-12-06 DK DK97103685T patent/DK0786474T3/en active 1990-12-06 CA CA002071875A patent/CA2071875C/en not_active Expired - Lifetime 1990-12-06 DK DK91901327T patent/DK0506757T4/en active 1990-12-06 AU AU70393/91A patent/AU645539B2/en not_active Expired 1990-12-06 DE DE69034040T patent/DE69034040T2/en not_active Expired - Lifetime 1990-12-06 ES ES91901327T patent/ES2119769T5/en not_active Expired - Lifetime 1990-12-06 EP EP91901327A patent/EP0506757B2/en not_active Expired - Lifetime 1990-12-06 EP EP02009162A patent/EP1293513A3/en not_active Withdrawn 1990-12-06 DE DE69032600T patent/DE69032600T3/en not_active Expired - Lifetime 1990-12-06 JP JP3501715A patent/JP2644084B2/en not_active Expired - Lifetime 1990-12-06 EP EP97103685A patent/EP0786474B1/en not_active Expired - Lifetime 1990-12-06 WO PCT/SE1990/000809 patent/WO1991009122A1/en active IP Right Grant 1990-12-06 SG SG9603152A patent/SG66753A1/en unknown 1990-12-06 ES ES97103685T patent/ES2189897T3/en not_active Expired - Lifetime 1990-12-06 DE DE1999175066 patent/DE19975066I2/en active Active 1990-12-06 AT AT97103685T patent/ATE232213T1/en not_active IP Right Cessation 1990-12-06 BR BR909007921A patent/BR9007921A/en unknown 1990-12-14 IE IE451090A patent/IE904510A1/en not_active IP Right Cessation 1990-12-14 PT PT96208A patent/PT96208B/en not_active IP Right Cessation 1992 1992-06-12 NO NO922325A patent/NO309041B1/en not_active IP Right Cessation 1992-06-12 FI FI922745A patent/FI104260B/en active 1995 1995-06-28 HU HU95P/P00489P patent/HU211504A9/en unknown 1998 1998-08-14 HK HK99104067A patent/HK1019449A1/en not_active IP Right Cessation 1998-08-14 HK HK98109933A patent/HK1009290A1/en not_active IP Right Cessation 1999 1999-10-12 NL NL990035C patent/NL990035I2/en unknown 1999-10-12 LU LU90457C patent/LU90457I2/en unknown Also Published As Publication number Publication date HK1019449A1 (en) 2000-02-11 ES2189897T3 (en) 2003-07-16 BR9007921A (en) 1992-11-10 DE69034040D1 (en) 2003-03-13 JPH05502161A (en) 1993-04-22 IE904510A1 (en) 1991-07-17 EP0786474B1 (en) 2003-02-05 DE69032600T3 (en) 2006-07-20 DE19975066I2 (en) 2005-07-07 NL990035I1 (en) 1999-12-01 ES2119769T3 (en) 1998-10-16 EP0506757B2 (en) 2005-10-26 LU90457I2 (en) 2001-04-13 DE69034040T2 (en) 2003-11-20 WO1991009122A1 (en) 1991-06-27 NO309041B1 (en) 2000-12-04 NZ236276A (en) 1993-03-26 EP0786474A1 (en) 1997-07-30 EP1293513A3 (en) 2003-04-02 JP2644084B2 (en) 1997-08-25 NO922325D0 (en) 1992-06-12 DK0506757T4 (en) 2006-02-20 PT96208B (en) 1998-05-29 FI922745A0 (en) 1992-06-12 PT96208A (en) 1991-09-30 EP0506757B1 (en) 1998-08-26 DK0506757T3 (en) 1999-05-25 DE69032600T2 (en) 1999-01-07 SE465222C5 (en) 1998-02-10 ES2119769T5 (en) 2006-04-16 SE8904239L (en) 1991-06-16 EP0506757A1 (en) 1992-10-07 DE69032600D1 (en) 1998-10-01 HU211504A9 (en) 1995-11-28 ATE232213T1 (en) 2003-02-15 ATE170219T1 (en) 1998-09-15 NL990035I2 (en) 2000-01-03 CA2071875C (en) 2006-08-08 NO922325L (en) 1992-08-11 CA2071875A1 (en) 1991-06-16 SG66753A1 (en) 2001-12-19 FI104260B1 (en) 1999-12-15 DK0786474T3 (en) 2003-03-03 EP1293513A2 (en) 2003-03-19 HK1009290A1 (en) 1999-05-28 SE8904239D0 (en) 1989-12-15 FI104260B (en) 1999-12-15 AU645539B2 (en) 1994-01-20 SE465222B (en) 1991-08-12 Similar Documents Publication Publication Date Title AU645539B2 (en) 1994-01-20 A recombinant human factor VIII derivative US5661008A (en) 1997-08-26 Recombinant human factor VIII derivatives EP0533862B1 (en) 1999-10-27 Recombinant human factor viii derivatives US6228620B1 (en) 2001-05-08 Protein complexes having factor VIII:C activity and production thereof US6060447A (en) 2000-05-09 Protein complexes having Factor VIII:C activity and production thereof AU656311B2 (en) 1995-02-02 Protein complexes having factor VIII:C activity and production thereof JP2872255B2 (en) 1999-03-17 High yield production method of factor VIII EP1673391B1 (en) 2008-12-10 MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES Legal Events Date Code Title Description 2002-03-21 PC Assignment registered Owner name: BIOVITRUM AB Free format text: FORMER OWNER WAS: PHARMACIA AND UPJOHN AKTIEBOLAG 2003-07-10 NA Applications received for extensions of time, section 223 Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20011017 TO 20030117 IN WHICH TO FILE THE PRESCRIBED DOCUMENTS HAS BEEN LODGED 2003-09-18 NB Applications allowed - extensions of time section 223(2) Free format text: THE TIME IN WHICH TO FILE THE PRESCRIBED DOCUMENTS HAS BEEN EXTENDED TO 20030117 2003-09-18 NC Extension of term for standard patent requested (sect. 70) Free format text: PRODUCT NAME: REFACTO 2004-04-29 NDA Extension of term for standard patent accepted (sect.70) Free format text: PRODUCT NAME: REFACTO MOROCTOCOG ALFA (RCH) Extension date: 20151206 2004-10-07 NDB Extension of term for standard patent granted (sect.76) Free format text: PRODUCT NAME: REFACTO MOROCTOCOG ALFA (RCH) Extension date: 20151206
Download PDF in English